Top

Journal of Neuro-Oncology

Published in:

01-09-2018 | Clinical Study

Retrospective study of nivolumab for patients with recurrent high grade gliomas

Authors: Megan Mantica, Ashley Pritchard, Frank Lieberman, Jan Drappatz

Published in: Journal of Neuro-Oncology | Issue 3/2018

Abstract

Introduction

Patients with recurrent high-grade gliomas (HGG) have limited treatment options. HGG utilize the PD-1 pathway to evade immune responses. Checkpoint inhibitors have demonstrated safety and clinical activity in patients with recurrent glioblastoma. We explored the efficacy of nivolumab in recurrent HGG with a primary objective of progression free survival (PFS) and overall survival (OS).

Methods

We retrospectively analyzed HGG patients treated with nivolumab in our institution. We included patients with advanced HGG who received nivolumab at their oncologist’s decision. Patients received nivolumab 3 mg/kg every 2 weeks until confirmed progression, intolerable toxicity, death, or physician decision. Radiographic assessments were performed every 8 weeks.

Results

Between April 2015 and October 2017, 50 HGG patients received nivolumab. 43 patients received nivolumab with bevacizumab. 44 patients were bevacizumab refractory and 7 patients received nivolumab monotherapy. All had received prior radiation and chemotherapy. 39 adverse events (AEs) were noted [most commonly fatigue (16%) and constipation (10%)]. 4 (8%) patients experienced grade 3–4 AEs. 36 (72%) patients experienced stable disease (SD) at the 2-month assessment. Median duration of SD was 4.3 months (5.1 months in the bevacizumab naïve, 3.8 months in the bevacizumab refractory). Median PFS was 4.3 months (95% CI 3.5–5.3); median OS was 6.5 months (95% CI 6.0–8.8).

Conclusion

Treatment with nivolumab therapy was associated with a manageable safety profile. In a subset of patients, there was disease stabilization in heavily pre-treated recurrent HGG.

Brandsma D, van den Bent MJ (2007) Molecular targeted therapies and chemotherapy in malignant gliomas. Curr Opin Oncol 19:598–605. https://doi.org/10.1097/CCO.0b013e3282f0313b CrossRefPubMed

Weller M, Cloughesy T, Perry JR, Wick W (2013) Standards of care for treatment of recurrent glioblastoma—are we there yet? Neuro Oncol 15:4–27. https://doi.org/10.1093/neuonc/nos273 CrossRefPubMed

Suchorska B, Weller M, Tabatabai G, Senft C, Hau P, Sabel MC, Herrlinger U, Ketter R, Schlegel U, Marosi C, Reifenberger G, Wick W, Tonn JC, Wirsching HG (2016) Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. Neuro Oncol 18:549–556. https://doi.org/10.1093/neuonc/nov326 CrossRefPubMedPubMedCentral

Clarke JL, Ennis MM, Yung WK, Chang SM, Wen PY, Cloughesy TF, Deangelis LM, Robins HI, Lieberman FS, Fine HA, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Lamborn KR, Prados MD, North American Brain Tumor C (2011) Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro Oncol 13:1118–1124. https://doi.org/10.1093/neuonc/nor110 CrossRefPubMed

Torcuator RG, Thind R, Patel M, Mohan YS, Anderson J, Doyle T, Ryu S, Jain R, Schultz L, Rosenblum M, Mikkelsen T (2010) The role of salvage reirradiation for malignant gliomas that progress on bevacizumab. J Neurooncol 97:401–407. https://doi.org/10.1007/s11060-009-0034-y CrossRefPubMed

Combs SE, Thilmann C, Edler L, Debus J, Schulz-Ertner D (2005) Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol 23:8863–8869. https://doi.org/10.1200/JCO.2005.03.4157 CrossRefPubMed

Fogh SE, Andrews DW, Glass J, Curran W, Glass C, Champ C, Evans JJ, Hyslop T, Pequignot E, Downes B, Comber E, Maltenfort M, Dicker AP, Werner-Wasik M (2010) Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol 28:3048–3053. https://doi.org/10.1200/JCO.2009.25.6941 CrossRefPubMedPubMedCentral

Reardon DA, Weller M (2015) Introduction. Neuro Oncol 17(Suppl 7):vii1. https://doi.org/10.1093/neuonc/nov261 CrossRefPubMedPubMedCentral

Han SJ, Rolston JD, Molinaro AM, Clarke JL, Prados MD, Chang SM, Berger MS, DeSilva A, Butowski NA (2014) Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma. Neuro Oncol 16:1255–1262. https://doi.org/10.1093/neuonc/nou044 CrossRefPubMedPubMedCentral

10.

van den Bent MJ, Taal W (2014) Are we done with dose-intense temozolomide in recurrent glioblastoma? Neuro Oncol 16:1161–1163. https://doi.org/10.1093/neuonc/nou157 CrossRefPubMedPubMedCentral

11.

Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779–787. https://doi.org/10.1212/01.wnl.0000304121.57857.38 CrossRefPubMed

12.

Chamberlain MC, Johnston SK (2010) Salvage therapy with single agent bevacizumab for recurrent glioblastoma. J Neurooncol 96:259–269. https://doi.org/10.1007/s11060-009-9957-6 CrossRefPubMed

13.

Nghiemphu PL, Liu W, Lee Y, Than T, Graham C, Lai A, Green RM, Pope WB, Liau LM, Mischel PS, Nelson SF, Elashoff R, Cloughesy TF (2009) Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 72:1217–1222. https://doi.org/10.1212/01.wnl.0000345668.03039.90 CrossRefPubMedPubMedCentral

14.

Quant EC, Norden AD, Drappatz J, Muzikansky A, Doherty L, Lafrankie D, Ciampa A, Kesari S, Wen PY (2009) Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol 11:550–555. https://doi.org/10.1215/15228517-2009-006 CrossRefPubMedPubMedCentral

15.

Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, Brandes AA, Taal W, Domont J, Idbaih A, Campone M, Clement PM, Stupp R, Fabbro M, Le Rhun E, Dubois F, Weller M, von Deimling A, Golfinopoulos V, Bromberg JC, Platten M, Klein M, van den Bent MJ (2017) Lomustine and Bevacizumab in progressive glioblastoma. N Engl J Med 377:1954–1963. https://doi.org/10.1056/NEJMoa1707358 CrossRefPubMed

16.

Field KM, Jordan JT, Wen PY, Rosenthal MA, Reardon DA (2015) Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies. Cancer 121:997–1007. https://doi.org/10.1002/cncr.28935 CrossRefPubMed

17.

Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–4740. https://doi.org/10.1200/JCO.2008.19.8721 CrossRefPubMed

18.

Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF (2006) MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66:1258–1260. https://doi.org/10.1212/01.wnl.0000208958.29600.87 CrossRefPubMed

19.

Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253–1259. https://doi.org/10.1158/1078-0432.CCR-06-2309 CrossRefPubMed

20.

Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722–4729. https://doi.org/10.1200/JCO.2007.12.2440 CrossRefPubMed

21.

Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740–745. https://doi.org/10.1200/JCO.2008.16.3055 CrossRefPubMed

22.

Chamberlain MC, Grimm S, Phuphanich S, Recht L, Zhu JZ, Kim L, Rosenfeld S, Fadul CE, Brain Tumor Investigational C (2014) A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the Brain Tumor Investigational Consortium (BTIC). J Neurooncol 118:335–343. https://doi.org/10.1007/s11060-014-1437-y CrossRefPubMed

23.

Chamberlain MC, Johnston SK (2011) Salvage therapy with single agent bendamustine for recurrent glioblastoma. J Neurooncol 105:523–530. https://doi.org/10.1007/s11060-011-0612-7 CrossRefPubMed

24.

Abdel-Rahman O, Fouad M (2015) Irinotecan-based regimens for recurrent glioblastoma multiforme: [corrected] a systematic review. Expert Rev Neurother 15:1255–1270. https://doi.org/10.1586/14737175.2015.1101346 CrossRefPubMed

25.

Field KM, Simes J, Nowak AK, Cher L, Wheeler H, Hovey EJ, Brown CS, Barnes EH, Sawkins K, Livingstone A, Freilich R, Phal PM, Fitt G, investigators CC, Rosenthal MA (2015) Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma. Neuro Oncol 17:1504–1513. https://doi.org/10.1093/neuonc/nov104 CrossRefPubMedPubMedCentral

26.

Lee EQ, Reardon DA, Schiff D, Drappatz J, Muzikansky A, Grimm SA, Norden AD, Nayak L, Beroukhim R, Rinne ML, Chi AS, Batchelor TT, Hempfling K, McCluskey C, Smith KH, Gaffey SC, Wrigley B, Ligon KL, Raizer JJ, Wen PY (2015) Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro Oncol 17:862–867. https://doi.org/10.1093/neuonc/nou350 CrossRefPubMedPubMedCentral

27.

Lassen U, Sorensen M, Gaziel TB, Hasselbalch B, Poulsen HS (2013) Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme. Anticancer Res 33:1657–1660PubMed

28.

Galanis E, Anderson SK, Lafky JM, Uhm JH, Giannini C, Kumar SK, Kimlinger TK, Northfelt DW, Flynn PJ, Jaeckle KA, Kaufmann TJ, Buckner JC (2013) Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial. Clin Cancer Res 19:4816–4823. https://doi.org/10.1158/1078-0432.CCR-13-0708 CrossRefPubMed

29.

Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32:1020–1030. https://doi.org/10.1200/JCO.2013.53.0105 CrossRefPubMedPubMedCentral

30.

Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, Margolin KA, Plimack ER, Lambert AM, Waxman IM, Hammers HJ (2015) Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol 33:1430–1437. https://doi.org/10.1200/JCO.2014.59.0703 CrossRefPubMed

31.

Rizvi NA, Mazieres J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS (2015) Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 16:257–265. https://doi.org/10.1016/S1470-2045(15)70054-9 CrossRefPubMedPubMedCentral

32.

Wolchok JD (2015) PD-1 Blockers. Cell 162:937. https://doi.org/10.1016/j.cell.2015.07.045 CrossRefPubMed

33.

Jin HT, Ahmed R, Okazaki T (2011) Role of PD-1 in regulating T-cell immunity. Curr Top Microbiol Immunol 350:17–37. https://doi.org/10.1007/82_2010_116 PubMedCrossRef

34.

Takita M, Matsumura T, Kami M (2006) Cytokine storm and an anti-CD28 monoclonal antibody. N Engl J Med 355:2593 (author reply 2593–2594)PubMed

35.

Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 372:311–319. https://doi.org/10.1056/NEJMoa1411087 CrossRefPubMed

36.

Reardon DA, Omuro A, Brandes AA, Rieger J, Wick A, Sepulveda J, Phuphanich S, de Souza P, Ahluwalia MS, Lim M, Vlahovic G, Sampson JH (2017) OS10.3 randomized phase 3 study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent glioblastoma: checkmate 143. Neuro Oncol 19:iii21. https://doi.org/10.1093/neuonc/nox036.071 CrossRefPubMedCentral

37.

Reardon D, Kim T, Frenel J, Santoro A, Lopez J, Subramaniam DS, Siu LL, Rodon J, Tamura K, Saraf S, Morosky A, Stein K, Soria J (2016) ATIM-35. Results of the phase IB Keynote-028 multi-cohort trial of pembrolizumab monotherapy in patients with recurrence PD-L1 positive glioblastoma multiforme (GBM). Neuro Oncol 18:vi25–vi26. https://doi.org/10.1093/neuonc/now212.100 CrossRef

38.

Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T, Voloschin A, Ramkissoon SH, Ligon KL, Latek R, Zwirtes R, Strauss L, Paliwal P, Harbison CT, Reardon DA, Sampsonc JH (2017) Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase 1 cohorts of CheckMate 143. Neuro Oncol. https://doi.org/10.1093/neuonc/nox208 CrossRefPubMedPubMedCentral

39.

Chamberlain MC, Kim BT (2017) Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series. J Neurooncol 133:561–569. https://doi.org/10.1007/s11060-017-2466-0 CrossRefPubMed

40.

Bouffet E, Larouche V, Campbell BB, Merico D, de Borja R, Aronson M, Durno C, Krueger J, Cabric V, Ramaswamy V, Zhukova N, Mason G, Farah R, Afzal S, Yalon M, Rechavi G, Magimairajan V, Walsh MF, Constantini S, Dvir R, Elhasid R, Reddy A, Osborn M, Sullivan M, Hansford J, Dodgshun A, Klauber-Demore N, Peterson L, Patel S, Lindhorst S, Atkinson J, Cohen Z, Laframboise R, Dirks P, Taylor M, Malkin D, Albrecht S, Dudley RW, Jabado N, Hawkins CE, Shlien A, Tabori U (2016) Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol 34:2206–2211. https://doi.org/10.1200/JCO.2016.66.6552 CrossRefPubMed

41.

Reardon D, Kaley TJ, Dietrich J, Jennifer LC, Dunn GP, Lim M, Cloughesy T, Gan HK, Park AJ, Schwarzenberger P, Ricciardo T, Macri MJ, Ryan A, Venhaus RR (2017) Phase 2 study to evaluate safety and efficacy of MEDI4736 (durvalumab [DUR]) in glioblastoma (GBM) patients: an update. J Clin Oncol 35:2042–2042. https://doi.org/10.1200/JCO.2017.35.15_suppl.2042 CrossRef

42.

Reardon D, de Groot J, Colman H, Jordan JT, Daras M, Clarke JL, Nghiemphu P, Gaffey SC, Peters KB (2016) Safety of pembrolizumab in combination with bevacizumab in recurrent glioblastoma (rGBM). J Clin Oncol 34:2010–2010. https://doi.org/10.1200/JCO.2016.34.15_suppl.2010 CrossRef

43.

Cloughesy JN, Prados M, Wen PY, Mikkelsen T, Abrey L, Schiff D, Yung WK, Maoxia Z, Dimery I, Friedman HS (2008) A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J Clin Oncol 26:2010b–2010b. https://doi.org/10.1200/jco.2008.26.15_suppl.2010b CrossRef

44.

Tonder M, Eisele G, Weiss T, Hofer S, Seystahl K, Valavanis A, Stupp R, Weller M, Roth P (2014) Addition of lomustine for bevacizumab-refractory recurrent glioblastoma. Acta Oncol 53:1436–1440. https://doi.org/10.3109/0284186X.2014.920960 CrossRefPubMed

Title: Retrospective study of nivolumab for patients with recurrent high grade gliomas
Authors: Megan Mantica
Ashley Pritchard
Frank Lieberman
Jan Drappatz
Publication date: 01-09-2018
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2018
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-018-2907-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Retrospective study of nivolumab for patients with recurrent high grade gliomas

Abstract

Introduction

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2018

Impact of surgery and radiation therapy on spinal high-grade gliomas: a population-based study

Bevacizumab rechallenge in glioblastoma patients with initial response to bevacizumab who later progress off therapy

Molecular classification of patients with grade II/III glioma using quantitative MRI characteristics

Post-gadolinium 3-dimensional spatial, surface, and structural characteristics of glioblastomas differentiate pseudoprogression from true tumor progression

Imaging practice in low-grade gliomas among European specialized centers and proposal for a minimum core of imaging

Post-treatment neutrophil-to-lymphocyte ratio predicts for overall survival in brain metastases treated with stereotactic radiosurgery